๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs

โœ Scribed by David P. Brooks; Todd A. Fredrickson; Joseph Weinstock; Robert R. Ruffolo; Richard M. Edwards; Miklos Gellai

Book ID
112274719
Publisher
Springer-Verlag
Year
1992
Tongue
English
Weight
614 KB
Volume
345
Category
Article
ISSN
0028-1298

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The pharmacokinetics and metabolism of D
The pharmacokinetics and metabolism of DuP 532, a non-peptide angiotensin II receptor antagonist, in rats and dogs
โœ Y. N. Wong; K. A. Holm; D. L. Burcham; S.-M. Huang; C. Y. Quon ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 481 KB ๐Ÿ‘ 1 views

DuP 532, 2-propy1-4-pentafluoroethyl-l-[ [2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylJ imidazole-5-carboxylic acid, is an orally active, non-peptide angiotensin I1 (AII) receptor antagonist. DuP 532 is more potent and longer acting than losartan, another A11 receptor antagonist currently undergoing ph

The pharmacokinetics and metabolism of C
The pharmacokinetics and metabolism of CP-191,166, an angiotensin II receptor antagonist, in rats and dogs
โœ Mary C. Allen; Mark R. Nocerini; Wesley W. Day ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 177 KB ๐Ÿ‘ 1 views

166 is an orally active, non-peptide angiotensin II (AII) receptor antagonist developed for the treatment of hypertension and congestive heart failure (CHF). In this study, the intravenous (iv) and oral (po) single dose pharmacokinetics (PK), oral multiple dose PK and P450-mediated metabolism of 16